Aurinia Pharmaceuticals (AUPH) Misses Q4 EPS by 3c, provides guidance

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of ($0.19), $0.03 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $45.1 million versus the consensus estimate of $44.2 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2024 revenue of $200-220 million, versus the consensus of $219.1 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours
• Nike updates Q4 fiscal 2026 outlook with tariff refund benefit